Medicare Coverage for Bladder Cancer: BCG, Surgery, Costs

Bladder cancer is, more than almost any other cancer, a Medicare disease. The median age at diagnosis is 73, roughly 90 percent of patients are over 55, and it is the fourth most common cancer in American men. It is also unusual in another way that matters enormously for your wallet: bladder cancer has one of the highest recurrence rates of any cancer — 30 to 70 percent for early-stage disease — which means treatment is rarely a single episode. It is a years-long relationship with your urologist involving repeated cystoscopies, repeated resections, maintenance drug instillations, and lifelong surveillance. Every one of those encounters generates Medicare cost-sharing, and understanding how Part A, Part B, and Part D divide the bills is the difference between predictable costs and a five-figure surprise.

This guide walks through the full pathway — from the first evaluation of blood in the urine through advanced immunotherapy — and what each step costs under Original Medicare, Medigap, and Medicare Advantage.

Why Bladder Cancer Is a Medicare-Age Disease

The single biggest risk factor is smoking, which accounts for roughly half of all bladder cancers. Carcinogens absorbed through the lungs are filtered by the kidneys and concentrated in urine, where they sit in contact with the bladder lining for hours at a time. The damage accumulates over decades, which is why the disease peaks in the 70s — often in former smokers who quit twenty years ago. Occupational exposures (aromatic amines used in dye, rubber, leather, and paint industries), chronic bladder inflammation, and prior pelvic radiation are additional risk factors concentrated in older adults.

If you are a current or former smoker on Medicare, two things are worth knowing. First, Medicare Part B covers smoking cessation counseling at no cost — up to eight sessions per year. Second, the lung and bladder share the same carcinogenic exposure; former smokers being followed for lung health should not ignore urinary symptoms. See Medicare coverage for COPD and lung disease for the respiratory side of the same risk profile.

The classic presenting symptom is painless blood in the urine (hematuria) — visible or found on a routine urinalysis. Unlike the painful hematuria of a kidney stone (see Medicare coverage for kidney stones), bladder cancer bleeding typically doesn’t hurt, which leads many patients to dismiss it. Any episode of visible painless hematuria in a Medicare-age adult warrants a full urological evaluation.

Part B: The Diagnostic Workup

Medicare Part B covers the complete evaluation of hematuria and suspected bladder cancer:

Urinalysis and urine cytology: Basic urinalysis (CPT 81001) confirms blood; urine cytology examines shed cells for malignancy. Both are Part B laboratory services covered 80/20 after the deductible.

Cystoscopy (CPT 52000): The core diagnostic test — a thin scope passed through the urethra to directly visualize the bladder lining. Performed in the urologist’s office under local anesthesia in most cases. Part B covers it at 80 percent of the Medicare-approved amount. This is the same procedure used to evaluate BPH and bladder outlet symptoms; see Medicare coverage for BPH and overactive bladder for the benign conditions that share this workup.

CT urogram: A CT scan with contrast timed to visualize the kidneys, ureters, and bladder (CPT 74178). It evaluates the upper urinary tract for tumors that cystoscopy cannot see. Covered under Part B.

Blue-light cystoscopy (Cysview): An enhanced cystoscopy using hexaminolevulinate, an imaging agent that makes cancerous tissue fluoresce pink under blue light, improving detection of flat carcinoma in situ that white-light cystoscopy misses. Medicare covers blue-light cystoscopy under Part B when performed in appropriate settings; availability varies by facility.

Your cost: 20 percent of the Medicare-approved amount for each service after the Part B deductible ($257 in 2026). Medigap Plan G reduces this to zero after the deductible. Because bladder cancer surveillance means repeating cystoscopy for years (more on this below), the coverage structure you choose gets multiplied across dozens of future procedures.

TURBT: The Procedure That Diagnoses and Treats

If cystoscopy finds a tumor, the next step is transurethral resection of bladder tumor (TURBT) — CPT 52234 (small), 52235 (medium), or 52240 (large tumor). Under anesthesia, the urologist passes a resectoscope through the urethra and shaves the tumor off the bladder wall. TURBT is simultaneously diagnostic (the resected tissue determines the stage and grade) and therapeutic (for early-stage disease, complete resection is the treatment).

TURBT is the most common bladder cancer procedure and is typically performed as hospital outpatient surgery under Part B. Combined surgeon, anesthesia, and facility fees commonly total $5,000–$15,000; your 20 percent coinsurance without a supplement runs roughly $1,000–$3,000. For high-grade or T1 tumors, guidelines recommend a repeat TURBT within two to six weeks to confirm no muscle invasion was missed — a second procedure with a second round of cost-sharing.

The pathology from TURBT divides bladder cancer into two fundamentally different diseases:

• Non-muscle-invasive bladder cancer (NMIBC) — about 75 percent of new diagnoses. Confined to the bladder lining. Treated with TURBT plus intravesical (inside-the-bladder) therapy and surveillance.
• Muscle-invasive bladder cancer (MIBC) — about 20 percent. The tumor has grown into the bladder muscle wall. Requires major surgery or chemoradiation.

Part B: Intravesical BCG — the Workhorse of Early Bladder Cancer

For intermediate- and high-risk NMIBC, the standard of care after TURBT is Bacillus Calmette-Guérin (BCG) — a live attenuated bacterium instilled directly into the bladder through a catheter, where it triggers an immune response against residual cancer cells. A typical course is six weekly induction instillations, followed by maintenance instillations (three weekly doses at 3, 6, and 12 months, continuing up to three years for high-risk disease).

Because BCG is administered by a physician, it is covered under Medicare Part B — not Part D. The drug and the instillation procedure (CPT 51720) each carry 20 percent coinsurance. Individual instillations are modest ($100–$300 in coinsurance per visit without a supplement), but a full three-year maintenance program involves 15–27 instillations, and the visits add up. Medicare Part B vs. Part D drugs explains the physician-administered drug distinction that governs almost every bladder cancer therapy.

The BCG shortage: Since 2019, the only U.S.-approved BCG strain (TICE) has been in chronic short supply. Urologists manage the shortage by splitting doses (one vial across two or three patients) and prioritizing high-risk patients for full courses. If your urologist proposes dose-split BCG or an alternative agent because of supply, that is standard practice — and the alternatives are also covered: intravesical gemcitabine, mitomycin C, and the increasingly used gemcitabine/docetaxel combination are all Part B when instilled in the office.

Part B: When BCG Stops Working

A substantial minority of patients develop BCG-unresponsive disease. Guideline-preferred bladder-sparing options — all physician-administered and all covered under Part B — include:

• Pembrolizumab (Keytruda): IV immunotherapy approved for BCG-unresponsive carcinoma in situ. List price runs roughly $11,000–$12,000 per infusion every three weeks; 20 percent coinsurance without a supplement is about $2,200+ per dose with no annual cap under Original Medicare alone.
• Nadofaragene firadenovec (Adstiladrin): A gene therapy instilled into the bladder once every three months, approved for BCG-unresponsive CIS. List price approaches $200,000 per year — making the 20 percent Part B coinsurance question existential without supplemental coverage.
• Nogapendekin alfa inbakicept (Anktiva): An IL-15 agonist approved in 2024 for use with BCG in BCG-unresponsive CIS. Also Part B.

This is where the Medigap decision made years earlier pays off or doesn’t: with Plan G, all of these therapies cost $0 after the annual Part B deductible. Without it, a year of Adstiladrin can generate $40,000 in coinsurance. Patients with limited income and assets should check Medicare Savings Programs, which can pick up Part B cost-sharing entirely for those who qualify.

Muscle-Invasive Disease: Surgery, Chemotherapy, and Bladder Preservation

Neoadjuvant chemotherapy: For muscle-invasive disease, cisplatin-based chemotherapy before surgery (gemcitabine-cisplatin or dose-dense MVAC) improves survival and is the guideline standard. IV chemotherapy infused in a clinic is covered under Part B with 20 percent coinsurance.

Radical cystectomy: Surgical removal of the bladder (plus prostate in men, often uterus and part of the vagina in women) with pelvic lymph node dissection. This is major inpatient surgery — typically a five-to-seven-day hospital stay covered under Part A (the $1,736 inpatient deductible in 2026 covers days 1–60), with the surgeon’s fee under Part B. The surgeon also constructs a urinary diversion: an ileal conduit draining to an external bag (most common), or a neobladder fashioned from intestine that allows near-normal voiding in selected patients.

Urostomy supplies: Patients with an ileal conduit need pouching systems, skin barriers, and accessories for life. These are covered as Part B durable medical equipment/prosthetics at 80 percent, from a Medicare-enrolled supplier, with quantity limits per month. This parallels the colostomy supply coverage described in our colorectal cancer guide — the same DME rules apply.

Trimodality therapy (bladder preservation): For selected patients — and for those too frail for cystectomy — maximal TURBT followed by concurrent chemoradiation offers comparable outcomes in appropriately chosen cases. Radiation therapy and radiosensitizing chemotherapy are both covered under Part B. A full radiation course (20–32 fractions) generates coinsurance on every fraction without a supplement; Medigap flattens this to $0 after the deductible.

For the general architecture of how Medicare covers cancer surgery, radiation, and the two-midnight inpatient rule, see Medicare coverage for cancer treatment.

Advanced and Metastatic Disease: The New Standard of Care

Treatment of metastatic bladder cancer changed fundamentally in 2023–2024:

• Enfortumab vedotin (Padcev) plus pembrolizumab is now the preferred first-line therapy for advanced urothelial cancer, after trial results showed it nearly doubled survival versus chemotherapy. Both are IV drugs covered under Part B. Combined list prices can exceed $50,000 per month — the largest Part B coinsurance exposure in this article for patients without supplemental coverage.
• Avelumab (Bavencio) maintenance after chemotherapy, and single-agent pembrolizumab or nivolumab in later lines, are likewise Part B infusions.
• Erdafitinib (Balversa): An oral targeted therapy for tumors with FGFR3 genetic alterations (found by Part B-covered tumor genomic profiling). As a self-administered pill, it falls under Part D — list price around $20,000+ per month, but the 2026 Part D annual out-of-pocket cap of $2,100 limits what you actually pay. Medicare Part D explained covers how the cap and monthly smoothing program work.

The Part B/Part D asymmetry deserves emphasis because it is the central financial fact of modern bladder cancer treatment: oral Part D drugs are capped at $2,100 per year; infused Part B drugs have no cap at all under Original Medicare alone. Your exposure on Part B drugs is governed entirely by whether you carry Medigap, qualify for a Medicare Savings Program, or have a Medicare Advantage out-of-pocket maximum.

Surveillance: The Cost That Never Ends

Because recurrence is so common, guidelines require cystoscopic surveillance for years — often for life. A typical high-risk schedule: cystoscopy every three months for two years, every six months through year five, then annually. Add periodic urine cytology and upper-tract imaging.

Under Original Medicare without a supplement, each surveillance cystoscopy generates 20 percent coinsurance (typically $40–$150 in the office setting). Under Medicare Advantage, each may carry a fixed specialist or procedure copay. Neither amount is alarming in isolation — but multiply by 15–20 procedures over a decade, plus the near-certainty of at least one recurrence requiring repeat TURBT and reinduction BCG, and the cumulative cost profile favors robust supplemental coverage more strongly than almost any other cancer.

Medigap vs. Medicare Advantage for Bladder Cancer

Original Medicare + Medigap Plan G: After the $257 Part B deductible, essentially every service in this article — cystoscopy, TURBT, BCG, pembrolizumab, Adstiladrin, cystectomy, radiation, urostomy supplies — costs $0. For a disease defined by recurring procedures and ultra-expensive Part B drugs, this is the strongest financial protection available.

Original Medicare alone: 20 percent of everything under Part B, uncapped. A single year that includes TURBT, BCG induction, and a pembrolizumab course can exceed $30,000 out of pocket.

Medicare Advantage: Covers everything Original Medicare covers, but expect prior authorization for TURBT, BCG-unresponsive agents, Padcev, and cystectomy; network restrictions on urologic oncologists and high-volume cystectomy centers (surgical volume measurably affects cystectomy outcomes); and per-service copays up to the plan’s out-of-pocket maximum (typically $5,000–$8,000 in-network). The annual maximum is genuine protection Original-Medicare-alone lacks — but the tradeoff is authorization friction at each treatment decision, and switching to Medigap after diagnosis usually requires medical underwriting. See Medicare Supplement vs. Advantage costs and Medicare Advantage HMO vs. PPO for the structural comparison.

What Bladder Cancer Costs Under Medicare: Summary Table

Costs are approximate 2026 estimates. Actual Medicare-approved rates vary by geographic area and setting.

Seven Steps for Navigating Bladder Cancer Under Medicare

1. Never ignore painless blood in the urine. Visible painless hematuria in a Medicare-age adult is bladder cancer until proven otherwise. The full workup — urinalysis, cytology, cystoscopy, CT urogram — is covered under Part B.

2. Ask for your stage and grade in writing after TURBT. NMIBC and MIBC are different diseases with different treatment paths and radically different cost profiles. Everything downstream depends on this pathology report.

3. If high-grade or T1, confirm a repeat TURBT is planned. Restaging resection within two to six weeks is guideline-standard and covered — and it changes management in up to a third of patients.

4. If BCG is proposed, ask about supply. Dose-splitting during the shortage is legitimate; ask whether you’ll receive full induction and what the maintenance plan is. If an alternative (gemcitabine/docetaxel) is offered, it’s covered under Part B the same way.

5. Request tumor genomic testing if disease advances. FGFR3 testing determines erdafitinib eligibility, and the testing itself is covered under Part B. Oral targeted therapy under Part D is capped at $2,100/year — sometimes making it the most affordable advanced option.

6. If cystectomy is recommended, seek a high-volume center. Outcomes correlate with surgical volume. Under Original Medicare you can go to any center that accepts Medicare nationwide; under Medicare Advantage, check network status first and use the plan’s appeal rights if the in-network options lack cystectomy volume.

7. Price your coverage against a decade of surveillance, not one year of treatment. Bladder cancer’s defining feature is recurrence. When comparing Medigap premiums against Medicare Advantage savings, model 15–20 surveillance cystoscopies, at least one recurrence, and the possibility of a Part B immunotherapy course.

Frequently Asked Questions

Does Medicare cover BCG treatment for bladder cancer? Yes. BCG is administered by a physician into the bladder, so it is covered under Medicare Part B — both the drug and the instillation procedure. You pay 20 percent coinsurance per instillation without a supplement; Medigap Plan G reduces it to $0 after the annual deductible.

Is TURBT covered by Medicare? Yes. Transurethral resection of bladder tumor is a covered Part B outpatient surgical procedure, including surgeon, anesthesia, and facility fees at 80 percent of Medicare-approved amounts. A guideline-recommended repeat TURBT for high-grade disease is also covered.

How often will Medicare pay for surveillance cystoscopy? Medicare covers surveillance cystoscopy at the medically necessary frequency for your risk level — every three months for high-risk disease is standard and covered. There is no arbitrary annual limit; coverage follows medical necessity documented by your urologist.

Does Medicare cover Keytruda for bladder cancer? Yes. Pembrolizumab (Keytruda) is covered under Part B for BCG-unresponsive non-muscle-invasive disease and for advanced urothelial cancer. As a Part B drug it carries 20 percent coinsurance with no annual cap under Original Medicare alone — supplemental coverage matters enormously here.

Are urostomy bags covered after bladder removal? Yes. Urostomy pouching systems, skin barriers, and accessories are covered under Part B as prosthetic devices at 80 percent, with monthly quantity limits, when purchased from a Medicare-enrolled supplier. Medigap covers the remaining 20 percent.

Will Medicare Advantage cover the same bladder cancer treatments? MA plans must cover everything Original Medicare covers, but they can require prior authorization (common for BCG-unresponsive agents, Padcev, and cystectomy) and restrict you to network providers. If you anticipate needing a high-volume cystectomy center outside your network, that’s a significant consideration — and switching to Medigap after a cancer diagnosis usually requires medical underwriting.

Bladder cancer combines three financially dangerous features: it strikes at Medicare age, it recurs for years, and its modern drugs sit overwhelmingly on the uncapped Part B side of the ledger. The clinical care is excellent and comprehensively covered — the variable is what share you pay. Sort out your supplemental coverage before you need it, insist on the guideline steps (repeat TURBT, genomic testing, high-volume surgery), and treat every surveillance cystoscopy as the cheap insurance it is. For the broader picture of how Medicare handles cancer care across all tumor types, start with Medicare coverage for cancer treatment — and if prostate symptoms rather than cancer brought you to this page, Medicare coverage for prostate cancer and our BPH guide cover the adjacent territory.